- Integer Holdings (ITGR, Financial) has appointed Michael Coyle to its Board of Directors, bringing over 40 years of medical device industry experience.
- Coyle will serve on several key committees, including Audit, Compensation & Organization, and Technology Strategy.
- Previously, Coyle was the CEO of iRhythm Technologies and EVP at Medtronic, holding six U.S. patents in cardiovascular technologies.
Integer Holdings Corporation (ITGR), a prominent medical device contract development and manufacturing organization (CDMO), has announced the appointment of Michael Coyle to its Board of Directors. Coyle, a seasoned veteran with over 40 years in the medical device industry, will enhance the board's capabilities by serving on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.
Coyle's distinguished career includes serving as the president and CEO of iRhythm Technologies, a leading digital healthcare company. He has also held significant roles such as the executive vice president and group president of Medtronic's cardio and vascular group, and leadership positions at St. Jude Medical and Eli Lilly.
In addition to his new role at Integer Holdings, Coyle serves on the boards of Haemonetics Corporation and BaroPace. He holds an MBA from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. With six U.S. patents to his name in cardiovascular medical device technologies, Coyle is expected to bring invaluable expertise to Integer's strategic initiatives aimed at revolutionizing patient care globally.
Integer Holdings, known for its commitment to innovative and high-quality medical solutions, continues to solidify its position as a partner of choice for medical device companies worldwide. The appointment of Coyle is anticipated to bolster the company's contract development and manufacturing outsourcing strategy, furthering its mission to enhance patient lives globally.
